News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Icagen, Inc. Provides Update Regarding Clinical Development Plans for ICA-105665
April 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
RESEARCH TRIANGLE PARK, N.C., April 27, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
Opinion
The Urgent Need To Redefine the Future of UK Biotech
October 1, 2025
·
6 min read
·
Kerstin Papenfuss
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
September 30, 2025
·
2 min read
·
Tristan Manalac
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
·
2 min read
·
Tristan Manalac
